The Oncology Institute, Inc. (TOI)
| Market Cap | 395.36M +39.5% |
| Revenue (ttm) | 545.76M +35.4% |
| Net Income | -30.10M |
| EPS | -0.37 |
| Shares Out | 98.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,448,315 |
| Open | 4.050 |
| Previous Close | 4.070 |
| Day's Range | 3.890 - 4.150 |
| 52-Week Range | 2.015 - 4.880 |
| Beta | 0.36 |
| Analysts | Strong Buy |
| Price Target | 6.67 (+66.75%) |
| Earnings Date | May 7, 2026 |
About TOI
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliativ... [Read more]
Financial Performance
In 2025, The Oncology Institute's revenue was $502.73 million, an increase of 27.79% compared to the previous year's $393.41 million. Losses were -$50.31 million, -5.09% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for TOI stock is "Strong Buy." The 12-month stock price target is $6.67, which is an increase of 66.75% from the latest price.
News
The Oncology Institute Earnings Call Transcript: Q1 2026
Q1 2026 saw 41% revenue growth, record specialty pharmacy performance, and profitability in Florida. Guidance for revenue, adjusted EBITDA, and free cash flow was reaffirmed or raised, with ongoing expansion in value-based contracts and AI-driven efficiencies.
The Oncology Institute Reports First Quarter 2026 Financial Results
CERRITOS, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, t...
Constellation Software Inc. and Topicus.Com Inc. Announce Results for Topicus.com Inc. for the First Quarter Ended March 31, 2026
TORONTO, May 05, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) in a joint release with Constellation Software Inc. (TSX:CSU) today announced financial results for Topicus.com Inc. (“Topicus” or...
The Oncology Institute Announces First Quarter 2026 Earnings Release Date and Conference Call
CERRITOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) a pioneer in value-based community oncology care, today announced that the company will release ...
The Oncology Institute Transcript: 25th Annual Needham Virtual Healthcare Conference
A value-based oncology provider is expanding rapidly through delegated contracts, especially in Florida, and expects significant growth in capitated revenue and profitability through 2028. The dispensary segment has become the largest revenue driver, and AI initiatives are set to enhance efficiency and margins.
Oncology Institute names Minh Merchant Chief Legal Officer
The Oncology Institute (TOI) announced that Minh Merchant has joined the organization as Chief Legal Officer. In this role, Merchant will oversee legal, regulatory, compliance and privacy functions as...
Oncology Institute price target raised to $8 from $6 at B. Riley
B. Riley raised the firm’s price target on Oncology Institute (TOI) to $8 from $6 and keeps a Buy rating on the shares. Oncology Institute delivered its first profitable quarter
The Oncology Institute Earnings Call Transcript: Q4 2025
Achieved first profitable quarter on adjusted EBITDA in Q4 2025, with revenue up 28% year-over-year and strong growth in pharmacy and capitated care. 2026 guidance projects continued revenue and margin expansion, with positive free cash flow expected by year-end.
The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026
CERRITOS, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States,...
Oncology Institute appoints Kim Tzoumakas to board of directors
The Oncology Institute (TOI) announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas is CEO for VytlOne National Pharmacy Service. Published fi...
U.S. Neurology Associates Partners with M33 Growth to Transform Neurological Care
DALLAS and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- M33 Growth, a Boston-based venture and growth-stage investment firm, today announced its partnership with U.S. Neurology Associates (“USNA” or the ...
Oncology Institute promotes Panda to CIO, Mariano to CPO
The Oncology Institute (TOI) announced the promotions of Rakesh Panda to Chief Information Officer, CIO, and Nolan Mariano to Chief People Officer, CPO.
The Oncology Institute Announces Leadership Promotions
Rakesh Panda appointed Chief Information Officer Nolan Mariano appointed Chief People Officer CERRITOS, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) announced t...
Oncology Institute appoints Mark Stolper to board of directors
The Oncology Institute (TOI) announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadersh...
Oncology Institute director Gabe Ling resigns
The Oncology Institute (TOI) announced that Gabe Ling has resigned from the Board of Directors, effective December 1, 2025. A formal search process has been initiated to add new independent
The Oncology Institute Announces Resignation of Board Member Gabe Ling
CERRITOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Gabe L...
Oncology Institute initiated with a Buy at Needham
Needham initiated coverage of Oncology Institute (TOI) with a Buy rating and $5 price target As value-based care adoption accelerates, Oncology Institute appears well positioned to help curb rising on...
Oncology Institute initiated with a Buy at Needham
Needham analyst Matthew Shea initiated coverage of Oncology Institute (TOI) with a Buy rating and $5 price target The need for solutions that can mitigate oncology cost trends “could not
The Oncology Institute Earnings Call Transcript: Q3 2025
Q3 2025 saw 36.7% revenue growth, record Pharmacy results, and improved adjusted EBITDA, with the first profitable month in September. Guidance for 2025 was raised, and operational momentum is strong, supported by new contracts, AI initiatives, and expanding payer relationships.
Ascertain and The Oncology Institute Co-Develop ‘Touchless' AI Automation for Oncology Administration
Partnership deployed touchless prior authorization system in eight weeks, achieving 95% reduction in authorization workload Partnership deployed touchless prior authorization system in eight weeks, ac...
The Oncology Institute Announces Third Quarter 2025 Earnings Release Date and Conference Call
CERRITOS, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), a pioneer in value-based community oncology care, today announced that the company will release...
The Oncology Institute Transcript: Noble Capital Markets Emerging Growth Virtual Investor Conference
Oncology care costs are rising unsustainably, but a value-based model with employed clinicians and proprietary care pathways is delivering significant cost savings, high patient satisfaction, and robust financial growth. Expansion focuses on existing high-utilization markets, with profitability projected in Q4.
Oncology Institute enters partnership with Protocol Behavioral Health
The Oncology Institute (TOI) announced a new partnership with Protocol Behavioral Health. Key Benefits of the Partnership: Integrated Care Delivery: Protocol clinicians collaborate with TOI providers ...
Oncology Institute achieves $1.1M in savings in CMS EOM Performance Period 2
The Oncology Institute (TOI) of Hope and Innovation achieved $1.1 million in Medicare savings during Performance Period 2 of the Centers for Medicare & Medicaid Services’ Enhancing Oncology Model thro...
The Oncology Institute Launches Lung Cancer Center of Excellence in Florida Led by International Oncology Expert Dr. Edgardo Santos
CERRITOS, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (NASDAQ: TOI), a leading value-based oncology practice, today announced the launch of its Lung Cancer...